ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Continuing Resolution Expires March 27; NIH, NCI Hope For Budget Compromise

March 15, 2013

Clinical Trials Approved By NCI CTEP Last Month

July 29, 2011

Cancer Education: NCI Offers Training In Epidemiology And Genetics

April 17, 1998

Funding Opportunities listed.

December 5, 2003

DCPC Board Will Consider Revised Concepts For CPRUs

September 18, 1987

NCAB Defends Organ Site Program, But DeVita Still Plan to Discuss It With Cancer Panel

October 17, 1980